newsfilter
← Latest News
GlobeNewswire·

Prevail Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

Opened Enrollment of PROPEL Phase 1/2 Trial of PR001 to Treat Parkinson’s Disease Patients with GBA1 Mutations PR001 for Neuronopathic Gaucher Disease and PR006 for Frontotemporal Dementia with GRN...